MRNA
Overvalued by 167.3% based on the discounted cash flow analysis.
Market cap | $39.05 Billion |
---|---|
Enterprise Value | $31.02 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-12.34 |
Beta | 1.07 |
Outstanding Shares | 382,879,612 |
Avg 30 Day Volume | 3,226,026 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -8.28 |
---|---|
PEG | 9.73 |
Price to Sales | 6.14 |
Price to Book Ratio | 2.9 |
Enterprise Value to Revenue | 4.53 |
Enterprise Value to EBIT | -7.32 |
Enterprise Value to Net Income | -7 |
Total Debt to Enterprise | 0.02 |
Debt to Equity | 0.04 |
No data
No data